Serum biomarker panels for the detection of pancreatic cancer

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 805-816

  Brand, Randall E ^a   Nolen, Brian M ^b,c   Zeh, Herbert J ^b   Allen, Peter J ^f,g   Eloubeidi, Mohamad A ^h   Goldberg, Michael ^j   Elton, Eric ^j   Arnoletti, Juan P ^g   Christein, John D ^g   Vickers, Selwyn M ^k   Langmead, Christopher J ^e   Landsittel, Douglas P ^d   Whitcomb, David C ^c,d   Grizzle, William E ⁱ   Lokshin, Anna E ^b,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Carnegie Mellon University   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Kentucky   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ University of Alabama at Birmingham   (United States)

^j NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; OSTEOPROTEGERIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79951833553     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0248     Document Type: Article

References (50)

1. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. (Accessed athttp://seer.cancer.gov/csr/1975-2006/.)
2. Grantzdorffer I, Carl-McGrath S, Ebert MP, Rocken C. Proteomics of pancreatic cancer. Pancreas 2008;36:329-36. (Pubitemid 351591573)
3. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004;59:99-111. (Pubitemid 39062369)
4. Sohn TA, Lillemoe KD. Surgical palliation of pancreatic cancer. Adv Surg 2000;34:249-71.
5. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
6. Larghi A, Verna EC, Lecca PG, Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009;15:1907-14.
7. Morganti AG, Valentini V, Macchia G, Alfieri S, Trodella L, Brizi MG, et al. Adjuvant radiotherapy in resectable pancreatic carcinoma. Eur J Surg Oncol 2002;28:523-30. (Pubitemid 35446782)
8. Brand RE, Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis Sci 1998;16:242-52. (Pubitemid 128531138)
9. Hanbidge AE. Cancer of the pancreas: the best image for early detection-CT, MRI, PET or US?Can J Gastroenterol 2002;16:101-5. (Pubitemid 34406659)
10. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70. (Pubitemid 46488663)
11. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-6. (Pubitemid 43166133)
12. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
13. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
14. Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 1999; 34:833-44.
15. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, Sudhir D, et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004;3:1254-61. (Pubitemid 41350962)
16. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000;89:83-8. (Pubitemid 30451277)
17. Zhou W, Sokoll LJ, Bruzek DJ, Zhang L, Velculescu VE, Goldin SB, et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998;7:109-12. (Pubitemid 28109841)
18. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008;98:1540-7. (Pubitemid 351652327)
19. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5:e123.
20. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13: 487-91. (Pubitemid 38737477)
21. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009;38:613-8.
22. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a Multimarker Assay for Early Detection of Ovarian Cancer. J Clin Oncol 2010.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
24. Brand RE. Screening for familial pancreatic cancer: is doing something better than doing nothing? Gut 2009;58:1321-2.
25. Joergensen MT, Brunner N, De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res; 30:587-92.
26. Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 2008;113:57-64.
27. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002;8:2306-10. (Pubitemid 34753605)
28. Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Current Pharmaceutical Des 2009;15:1949-55.
29. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7. (Pubitemid 36019639)
30. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 2006;54:63-73. (Pubitemid 43049416)
31. Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGerald O, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006;54: 105-14. (Pubitemid 43122193)
32. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984;19:193-8. (Pubitemid 14171511)
33. Miyake K, Imura S, Nishioka M, Batmunkh E, Sugimoto K, Ohmoto Y, et al. Serum evaluation of soluble interferon-alpha/beta receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine 2010;49:251-5.
34. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005;5:514-29. (Pubitemid 41407282)
35. McDade TP, Perugini RA, Vittimberga FJ Jr., Carrigan RC, Callery MP. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res 1999;83:56-61. (Pubitemid 29394107)
36. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003;22:765-71.
37. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001; 477:7-21. (Pubitemid 32480184)
38. Talamini G, Bassi C, Falconi M, Sartori N, Salvia R, Rigo L, et al. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci 1999;44:1303-11. (Pubitemid 29404289)
39. Yan L, Tonack S, Smith R, Dodd S, Jenkins RE, Kitteringham N, et al. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 2009;8:142-8.
40. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg 2005; 15:692-9. (Pubitemid 40847960)
41. Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 1999;880:288-307. (Pubitemid 29349137)
42. van Grevenstein WM, Hofland LJ, Jeekel J, van Eijck CH. The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas 2006;32:396-402. (Pubitemid 43772196)
43. Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol 2009;24:900-11.
44. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Koike Y, Yokoe T, et al. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol 2008;15:1617-24.
45. Ozer G, Altinel M, Kocak B, Balci M, Altan A, Gonenc F. Potential value of soluble intercellular adhesion molecule-1 in the serum of patients with bladder cancer. Urol Int 2003;70:167-71. (Pubitemid 36359545)
46. Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, Kato Y, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 1998;4:31-6. (Pubitemid 28062874)
47. van Groningen JJ, Klink SL, Bloemers HP, Swart GW. Expression of tissue-type transglutaminase correlates positively with metastatic properties of human melanoma cell lines. Int J Cancer 1995; 60:383-7.
48. Zirvi KA, Keogh JP, Slomiany A, Slomiany BL. Transglutaminase activity in human colorectal carcinomas of differing metastatic potential. Cancer Lett 1991;60:85-92.
49. Mehta K. Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer. Amino Acids 2009;36:709-16.
50. Cheung W, Darfler MM, Alvarez H, Hood BL, Conrads TP, Habbe N, et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008;8:608-16.